No business profile yet.
Size SunMax Biotechnology (4728.TWO) is a Taiwan Health Care company (Medical Specialties) with a market value of $630M, the 359th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$384.50 on 18 Nov 2026.
Performance Over six months the shares was unchanged, against -9.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 18.9% over the last twelve months (peer median +16.2%); the operating margin is 51.0% (peer median 9.5%).
Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.8× (4th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 118.0 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$2.37B | NT$2.03B | NT$1.82B | NT$1.69B | NT$1.40B |
| Revenue growth | — | +11% | +8% | +21% | — |
| Gross profit | NT$1.85B | NT$1.55B | NT$1.44B | NT$1.36B | NT$1.15B |
| EBITDA | NT$1.33B | NT$1.10B | NT$1.03B | NT$967M | NT$826M |
| Net income | NT$898M | NT$726M | NT$679M | NT$626M | NT$534M |
| Free cash flow | NT$959M | NT$766M | NT$534M | NT$743M | NT$494M |
| Capital expenditure | NT$101M | NT$79.0M | NT$39.7M | NT$140M | NT$155M |
| Total debt | NT$108M | NT$119M | NT$145M | NT$174M | NT$70.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4728.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.5% | -0.1% | 8th lowest of 19 |
| 6-month return | 0.0% | -9.3% | 8th highest of 19 |
| Distance from 52-week high | -10.4% | -26.0% | 5th highest of 20 |
| Revenue growth (TTM) | +18.9% | +16.2% | 8th highest of 20 |
| Operating margin | 51.0% | 9.5% | highest of 20 |
| EV / Sales | 8.3× | 3.8× | 4th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | -2.6% | 7.5% | 3rd least demanding of 13 |
| Growth delivered (Del g) | +18.8% | +13.7% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | -21.5 pp | -7.5 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +118.0 pp | +2.0 pp | highest of 19 |
| EV / EBITDA | 14.9× | 17.7× | 5th cheapest of 9 |
| Net debt / EBITDA | -0.7× | -1.2× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | 8.3× | -2.6% | +18.8% |
| Beijing Chunlizhengda Medical Instruments 1858.HK | Hong Kong | $631M | -28% | -9% | 31% | 2.3× | -9.5% | +1.5% |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 2.1× | -11.5% | +6.7% |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 6.3× | 35.9% | +35.2% |
| QuidelOrtho QDEL | United States | $657M | -20% | -5% | -2% | 1.4× | n/a | n/a |
| Synektik SNT.WA | Poland | $662M | +10% | +32% | 24% | 2.9× | 0.2% | +47.5% |
| Shanghai Kinetic Medical 300326.SZ | China | $662M | -10% | -28% | 17% | 3.8× | 6.6% | -1.9% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 3.8× | 35.3% | +6.7% |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 7.1× | -1.2% | +14.5% |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | 6.4× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $680M | -9% | +29% | 5% | 1.6× | 10.1% | +14.2% |
| Delcath Systems DCTH | United States | $685M | +75% | +38% | 5% | 5.3× | 33.4% | +120.2% |
| Livsmed 491000.KS | South Korea | $687M | -47% | +89% | -77% | 18.1× | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Shenzhen Lifotronic Technology 688389.SS | China | $692M | -14% | +14% | 13% | 3.0× | 11.6% | +13.3% |